hVIVO plc (LON:HVO – Get Free Report)’s stock price was up 3.5% during trading on Wednesday . The company traded as high as GBX 20.60 ($0.26) and last traded at GBX 20.50 ($0.26). Approximately 1,418,431 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 3,544,421 shares. The stock had previously closed at GBX 19.80 ($0.25).
hVIVO Trading Up 1.2 %
The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm has a market cap of £146.28 million, a price-to-earnings ratio of 730.00 and a beta of 0.97. The company has a 50 day moving average price of GBX 27.21 and a 200 day moving average price of GBX 27.84.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Articles
- Five stocks we like better than hVIVO
- 3 Stocks to Consider Buying in October
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Why Invest in 5G? How to Invest in 5G Stocks
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- High Flyers: 3 Natural Gas Stocks for March 2022
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
